Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Wave Life Sci Ord Sh
(NQ:
WVE
)
15.31
+0.70 (+4.79%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,033,771
Open
14.66
Bid (Size)
15.20 (5)
Ask (Size)
15.45 (5)
Prev. Close
14.61
Today's Range
14.25 - 15.39
52wk Range
3.500 - 15.92
Shares Outstanding
98,983,261
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Wave Life Sciences Rockets 70% on Historic RNA Editing Success
October 18, 2024
Wave Life Sciences' RNA editing advances have generated investor interest as the company strives to become a leading force in the treatment of genetic diseases.
Via
MarketBeat
This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
October 16, 2024
Via
Benzinga
Performance
YTD
+186.70%
+186.70%
1 Month
+179.89%
+179.89%
3 Month
+162.16%
+162.16%
6 Month
+214.37%
+214.37%
1 Year
+180.40%
+180.40%
More News
Read More
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 16, 2024
Via
Benzinga
Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans
October 16, 2024
Via
Benzinga
Deep Dive Into WAVE Life Sciences Stock: Analyst Perspectives (4 Ratings)
August 09, 2024
Via
Benzinga
Wave Life Sciences Just Edited RNA — And Shares Hit The Stratosphere
October 16, 2024
Via
Investor's Business Daily
United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday
October 16, 2024
Via
Benzinga
Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
October 16, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024
October 16, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Better Biotech Stock: Wave Life Sciences vs. Sarepta Therapeutics
October 03, 2024
Via
The Motley Fool
Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 01, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference
September 30, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
September 25, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
General Motors To $42? Here Are 10 Top Analyst Forecasts For Wednesday
September 25, 2024
Via
Benzinga
Stitch Fix Reports Weak Earnings, Joins KB Home And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
September 25, 2024
Via
Benzinga
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
September 24, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Crude Oil Gains Over 1%; BioVie Shares Plunge
September 24, 2024
Via
Benzinga
Exposures
Fossil Fuels
Nasdaq Surges 100 Points; Thor Industries Earnings Top Views
September 24, 2024
Via
Benzinga
Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug
September 24, 2024
Via
Benzinga
Wave Life Sciences, Nio, Li Auto, Tesla And Other Big Stocks Moving Higher On Tuesday
September 24, 2024
Via
Benzinga
Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
September 24, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
September 20, 2024
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Gene Editing Korro Bio's Preclinical Data 'Best-In-Class', Analyst Initiates With Outperform Rating
August 14, 2024
Via
Benzinga
Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy
August 12, 2024
From
Wave Life Sciences USA, Inc.
Via
GlobeNewswire
WVE Stock Earnings: WAVE Life Sciences Misses EPS, Misses Revenue for Q2 2024
August 08, 2024
Via
InvestorPlace
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.